- Previous Close
52.53 - Open
52.60 - Bid 37.52 x 200
- Ask 65.34 x 200
- Day's Range
50.72 - 53.58 - 52 Week Range
24.22 - 60.60 - Volume
722,619 - Avg. Volume
958,410 - Market Cap (intraday)
3.134B - Beta (5Y Monthly) 2.33
- PE Ratio (TTM)
12.07 - EPS (TTM)
4.23 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
69.10
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
www.protagonist-inc.comRecent News: PTGX
View More
Performance Overview: PTGX
Trailing total returns as of 3/25/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PTGX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PTGX
View MoreValuation Measures
Market Cap
3.13B
Enterprise Value
2.73B
Trailing P/E
12.07
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.65
Price/Book (mrq)
4.64
Enterprise Value/Revenue
6.27
Enterprise Value/EBITDA
10.66
Financial Highlights
Profitability and Income Statement
Profit Margin
63.34%
Return on Assets (ttm)
28.66%
Return on Equity (ttm)
54.39%
Revenue (ttm)
434.43M
Net Income Avi to Common (ttm)
275.19M
Diluted EPS (ttm)
4.23
Balance Sheet and Cash Flow
Total Cash (mrq)
418.91M
Total Debt/Equity (mrq)
1.61%
Levered Free Cash Flow (ttm)
65.11M
Research Analysis: PTGX
View MoreCompany Insights: PTGX
PTGX does not have Company Insights
Research Reports: PTGX
View MoreLowering target price to $57.00
PROTAGONIST THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $57.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetRating increased to a HOLD
PROTAGONIST THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $59.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetRating decreased to a SELL
PROTAGONIST THERAPEUTICS INC has an Investment Rating of SELL; a target price of $31.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetLowering target price to $37.00
PROTAGONIST THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $37.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target